NEWTON, Mass.--(BUSINESS WIRE)--Dec. 5, 2005--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Food and Drug Administration (FDA) agreed that advancing NOV-002 into a single pivotal Phase 3 study in advanced non-small cell lung cancer (NSCLC), in combination with first-line chemotherapy, is warranted at this time. The FDA also provided helpful feedback regarding the prospective New Drug Application (NDA) filing for NOV-002.
